CA2382567A1 - Utilisation d'au moins une substance a base de nicotine et/ou d'une substance produite a partir de la substance precitee et destinee a la preparation d'un medicament et methode de traitement de maladies pulmonaires obstructives - Google Patents
Utilisation d'au moins une substance a base de nicotine et/ou d'une substance produite a partir de la substance precitee et destinee a la preparation d'un medicament et methode de traitement de maladies pulmonaires obstructives Download PDFInfo
- Publication number
- CA2382567A1 CA2382567A1 CA002382567A CA2382567A CA2382567A1 CA 2382567 A1 CA2382567 A1 CA 2382567A1 CA 002382567 A CA002382567 A CA 002382567A CA 2382567 A CA2382567 A CA 2382567A CA 2382567 A1 CA2382567 A1 CA 2382567A1
- Authority
- CA
- Canada
- Prior art keywords
- nicotine
- medicament
- substance
- intended
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 54
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 229960002715 nicotine Drugs 0.000 title claims abstract description 49
- 239000000126 substance Substances 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 15
- 208000011623 Obstructive Lung disease Diseases 0.000 title claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- 206010014561 Emphysema Diseases 0.000 claims abstract description 13
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 5
- 230000002146 bilateral effect Effects 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 6
- 206010010356 Congenital anomaly Diseases 0.000 claims description 5
- 239000007857 degradation product Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 description 26
- 210000000621 bronchi Anatomy 0.000 description 14
- 210000002345 respiratory system Anatomy 0.000 description 14
- 230000000391 smoking effect Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000006378 damage Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 201000003144 pneumothorax Diseases 0.000 description 8
- 206010061688 Barotrauma Diseases 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 239000003570 air Substances 0.000 description 6
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 210000004224 pleura Anatomy 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000005586 smoking cessation Effects 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000003898 Mediastinal Emphysema Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010050184 Pneumomediastinum Diseases 0.000 description 1
- 206010048731 Pneumopericardium Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000000260 interstitial emphysema Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- -1 nicotine compound Chemical class 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000005801 respiratory difficulty Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne l'utilisation d'au moins une substance à base de nicotine et/ou d'une substance produite à partir de la substance précitée et destinée à la préparation d'un médicament à administrer à une personne ou à un animal afin de neutraliser, de manière prophylactique ou thérapeutique, des maladies pulmonaires obstructives, en particulier l'emphysème pulmonaire. Le médicament est conçu pour être libéré dans le sang et administré par le tube digestif, par voie transdermique, intravasculaire, intranasale ou intravaginale. L'invention concerne également une méthode de traitement prophylactique ou thérapeutique de maladies pulmonaires obstructives chez une personne ou un animal, selon laquelle on administre à cette personne une substance à base de nicotine.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9903085-0 | 1999-09-01 | ||
| SE9903085A SE516807C2 (sv) | 1999-09-01 | 1999-09-01 | Användning av åtminstone ett nikotinbaserat ämne och/eller ett ur detta ämne framställt ämne för tillverkning av ett medikament |
| SE0001075-1 | 2000-03-27 | ||
| SE0001075A SE0001075D0 (sv) | 1999-09-01 | 2000-03-27 | Användning av åtminstone ett nikotinbaserat ämne och/eller ett ur detta ämne framställt ämne för tillverkning av ett medikament samt förfarande för behandling av obstruktiva lungsjukdomar |
| PCT/SE2000/001683 WO2001015697A1 (fr) | 1999-09-01 | 2000-09-01 | Utilisation d'au moins une substance a base de nicotine et/ou d'une substance produite a partir de la substance precitee et destinee a la preparation d'un medicament et methode de traitement de maladies pulmonaires obstructives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2382567A1 true CA2382567A1 (fr) | 2001-03-08 |
Family
ID=26655041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002382567A Abandoned CA2382567A1 (fr) | 1999-09-01 | 2000-09-01 | Utilisation d'au moins une substance a base de nicotine et/ou d'une substance produite a partir de la substance precitee et destinee a la preparation d'un medicament et methode de traitement de maladies pulmonaires obstructives |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1207883A1 (fr) |
| AU (1) | AU7047700A (fr) |
| CA (1) | CA2382567A1 (fr) |
| SE (1) | SE0001075D0 (fr) |
| WO (1) | WO2001015697A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006005195A1 (fr) * | 2004-07-15 | 2006-01-19 | UNIVERSITé LAVAL | Agonistes du recepteur de nicotine pour le traitement de maladies inflammatoires |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2341952A1 (fr) * | 2001-03-23 | 2002-09-23 | Universite Laval | Agonistes du recepteur de la nicotine pour le traitement des maladies pulmonaires inflammatoires |
| US8557804B2 (en) | 2002-03-25 | 2013-10-15 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US8039459B2 (en) | 2004-07-15 | 2011-10-18 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998034615A1 (fr) * | 1997-02-07 | 1998-08-13 | Synapse Pharmaceuticals International, Inc. | Composition pharmaceutique contenant de l'oxime, pour le traitement de dysfonctionnement synaptique |
-
2000
- 2000-03-27 SE SE0001075A patent/SE0001075D0/xx unknown
- 2000-09-01 AU AU70477/00A patent/AU7047700A/en not_active Abandoned
- 2000-09-01 CA CA002382567A patent/CA2382567A1/fr not_active Abandoned
- 2000-09-01 WO PCT/SE2000/001683 patent/WO2001015697A1/fr not_active Application Discontinuation
- 2000-09-01 EP EP00959096A patent/EP1207883A1/fr not_active Withdrawn
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006005195A1 (fr) * | 2004-07-15 | 2006-01-19 | UNIVERSITé LAVAL | Agonistes du recepteur de nicotine pour le traitement de maladies inflammatoires |
| KR100860903B1 (ko) * | 2004-07-15 | 2008-09-29 | 유니버시티 라발 | 염증성 질환 치료용 니코틴성 수용체 효능제 |
| AU2005262174B2 (en) * | 2004-07-15 | 2009-10-08 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| AU2005262174C1 (en) * | 2004-07-15 | 2010-05-06 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| CN101001843B (zh) * | 2004-07-15 | 2014-08-27 | 拉瓦尔大学 | 用于治疗炎性疾病的烟碱受体激动剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| SE0001075D0 (sv) | 2000-03-27 |
| WO2001015697A1 (fr) | 2001-03-08 |
| AU7047700A (en) | 2001-03-26 |
| WO2001015697A8 (fr) | 2002-01-03 |
| EP1207883A1 (fr) | 2002-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bentur et al. | Controlled trial of nebulized albuterol in children younger than 2 years of age with acute asthma | |
| JP3718491B2 (ja) | 吸入用装置 | |
| Prosise et al. | Oral-nasal continuous positive airway pressure as a treatment for obstructive sleep apnea | |
| Walpole et al. | Effect of sevoflurane concentration on inhalation induction of anaesthesia in the elderly | |
| Wong et al. | No objective benefit from steroids inhaled via a spacer in infants recovering from bronchiolitis | |
| JP2007523079A (ja) | 睡眠障害性呼吸の治療および診断方法、およびこの方法を実施する手段 | |
| Greenspun et al. | Comparison of sevoflurane and halothane anesthesia in children undergoing outpatient ear, nose, and throat surgery | |
| Dreyfuss et al. | Should the lung be rested or recruited? The Charybdis and Scylla of ventilator management. | |
| Ruffin et al. | Site of beta-adrenergic receptors in the respiratory tract: use of fenoterol administered by two methods | |
| Luisada et al. | Alcohol vapor by inhalation in the treatment of acute pulmonary edema | |
| Egesa et al. | Bubble Nasal Continuous Positive Airway Pressure (bNCPAP): An Effective Low‐Cost Intervention for Resource‐Constrained Settings | |
| TW202233167A (zh) | 血管疾病治療用組成物、血管疾病預防用組成物、高血壓治療用組成物，及高血壓預防用組成物 | |
| Suske et al. | Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant‐substituted preterm infants | |
| Mouloudi et al. | Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of flow pattern | |
| Tierney et al. | Obstructive sleep apnoea | |
| CA2382567A1 (fr) | Utilisation d'au moins une substance a base de nicotine et/ou d'une substance produite a partir de la substance precitee et destinee a la preparation d'un medicament et methode de traitement de maladies pulmonaires obstructives | |
| JP3168543B2 (ja) | バスピロン：睡眠誘起性無呼吸症剤 | |
| Chapman | Therapeutic approaches to chronic obstructive pulmonary disease: an emerging consensus | |
| O’Doherty et al. | Does inhalation of pentamidine in the supine position increase deposition in the upper part of the lung? | |
| Hargreaves et al. | Responses of airway rapidly adapting receptors to bradykinin before and after administration of enalapril in rabbits | |
| Sackner | Mucociliary transport | |
| Bruschi et al. | Levodropropizine does not affect P0. 1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment | |
| SU1701320A1 (ru) | Способ купировани приступа бронхиальной астмы | |
| McLeod et al. | Characterization of nasal obstruction in the allergic guinea pig using the forced oscillation method | |
| US20220362222A1 (en) | Once daily formulations of tacrolimus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20070904 |
|
| FZDE | Discontinued |
Effective date: 20070904 |